The results of the EU survey on the availability of age-appropriate medication for children with autoimmune liver disease (AILD) were recently published with the Journal of Hepatology. In conclusion, the letter to the editor, ‘Children with autoimmune liver disease have limited access to age-appropriate drug formulations, results from a European survey’ demonstrates that the use of marketed age-appropriate formulations, mainly for first-line and second-line drugs in the treatment of AILD, is limited in Europe and is not in keeping with the European Union Paediatric Regulation guidelines. The letter underlines the need for further national and international initiatives coordinated by professional societies, regulatory agencies and patient interest groups to investigate the reasons underlying current practices as well as to promote the availability and use of age-appropriate treatment modalities for children with AILD in Europe.